PMID: 8944468Oct 1, 1996Paper

Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing

The British Journal of Surgery
H TanakaT Takahashi

Abstract

The ability of the angiogenesis inhibitor TNP-470 to prevent liver metastasis after partial hepatectomy, and whether TNP-470 impairs liver regeneration or skin wound healing, was evaluated. Following the injection of VX2 carcinoma cells into the portal vein of rabbits, half of the animals underwent resection of the middle hepatic lobe (hepatectomized group) and half did not (non-hepatectomized group). TNP-470 (50 mg) was infused continuously into the portal vein in both groups for 7 days, while controls received only water. The hepatectomized TNP-470-treated group had significantly fewer tumours (mean(s.e.m.) 23.3(12.3)) than the hepatectomized control group (123.7(24.4)). There was no significant difference in the 5-bromo-2'-deoxyuridine labelling index of regenerated hepatocytes between the TNP-470-treated and control groups. Wound healing in TNP-470-treated animals was not impaired. Intraportal infusion of TNP-470 prevents the recurrence of liver metastasis after partial hepatectomy without impairing healing or liver regeneration.

References

Mar 1, 1975·Archivum Histologicum Japonicum = Nihon Soshikigaku Kiroku·M Muto
Mar 1, 1992·The British Journal of Surgery·Y PanisB Nordlinger
Feb 14, 1991·Biochemical and Biophysical Research Communications·M KusakaJ Folkman
Nov 1, 1990·The British Journal of Surgery·J ScheeleA Altendorf-Hofmann
Jan 1, 1985·Advances in Cancer Research·J Folkman
Sep 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W W Lautt, C V Greenway
Feb 1, 1994·The British Journal of Surgery·F G Que, D M Nagorney

❮ Previous
Next ❯

Citations

Feb 27, 2004·Biochimica Et Biophysica Acta·Jarmila D W van der Bilt, Inne H M Borel Rinkes
Nov 4, 2000·Expert Opinion on Investigational Drugs·E A Kruger, W D Figg
Dec 27, 2011·International Journal of Oral and Maxillofacial Surgery·Z GeK-Z Liu
Sep 6, 2005·The Journal of Surgical Research·Jason KoBruce Klitzman
May 19, 2000·The Journal of Surgical Research·A C BergerS K Libutti
Mar 26, 2005·Journal of Dental Research·A M SzpaderskaL A DiPietro
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A BurgerSharon X Liang
Aug 25, 2005·Journal of Surgical Oncology·Frank A ScappaticciHerbert Hurwitz
Jun 10, 2004·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Annette SchmidtWilhelm Bloch
Nov 1, 2011·Journal of Neurosurgery·Annick Desjardins, John H Sampson
May 13, 1999·International Journal of Experimental Pathology·P Gervaz, C Fontolliet
Nov 28, 2002·Annals of Surgery·Tom A DrixlerInne H M Borel Rinkes
Dec 5, 2014·World Journal of Gastroenterology : WJG·Ji-Hua Shi, Pål-Dag Line

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.